TABLE 4.
Top 5 most important features for each antibiotic model.
| ARGC | Gain |
| Cefepime | |
| AAC(6′)-Ib family aminoglycoside 6′-N-acetyltransferase | 18.90 ± 3.27 |
| Class A extended-spectrum beta-lactamase CTX-M-222 | 7.84 ± 1.07 |
| Aminoglycoside O-phosphotransferase APH(3″)-Ib | 6.44 ± 1.91 |
| Class C extended-spectrum beta-lactamase EC-18 | 5.49 ± 1.30 |
| Carbapenem-hydrolyzing class A beta-lactamase KPC-33 | 5.14 ± 1.32 |
| Cefotaxime | |
| Aminoglycoside nucleotidyltransferase ANT(3″)-IIa | 17.09 ± 7.27 |
| AAC(6′)-Ib family aminoglycoside 6′-N-acetyltransferase | 13.75 ± 7.65 |
| Class C extended-spectrum beta-lactamase EC-18 | 13.16 ± 4.84 |
| Multidrug efflux RND transporter permease subunit OqxB21 | 9.74 ± 4.27 |
| OXA-51 family carbapenem-hydrolyzing class D beta-lactamase OXA-561 | 8.26 ± 3.86 |
| Ceftriaxone | |
| AAC(6′)-Ib family aminoglycoside 6′-N-acetyltransferase | 15.52 ± 4.35 |
| Class C beta-lactamase CMY-163 | 8.76 ± 1.79 |
| Class A extended-spectrum beta-lactamase CTX-M-222 | 8.37 ± 2.17 |
| Class C extended-spectrum beta-lactamase EC-18 | 8.10 ± 1.99 |
| Multidrug efflux RND transporter permease subunit OqxB21 | 7.00 ± 3.20 |
| Ciprofloxacin | |
| AAC(6′)-Ib family aminoglycoside 6′-N-acetyltransferase | 23.44 ± 4.94 |
| Sulfonamide-resistant dihydropteroate synthase Sul1 | 10.29 ± 3.20 |
| Tetracycline efflux MFS transporter Tet(B) | 4.99 ± 1.71 |
| Class A beta-lactamase TEM-219 | 4.93 ± 1.14 |
| Aminoglycoside O-phosphotransferase APH(3″)-Ib | 4.47 ± 1.63 |
| Gentamicin | |
| Aminoglycoside N-acetyltransferase AAC(3)-IIc | 28.79 ± 3.10 |
| ANT(3″)-Ia family aminoglycoside nucleotidyltransferase AadA1 | 20.98 ± 2.52 |
| Aminoglycoside nucleotidyltransferase ANT(2”)-Ia | 17.79 ± 2.03 |
| OXA-24 family carbapenem-hydrolyzing class D beta-lactamase OXA-25 | 4.15 ± 1.59 |
| Mph(E) family macrolide 2’-phosphotransferase | 2.07 ± 1.10 |
| Levofloxacin | |
| AAC(6′)-Ib family aminoglycoside 6′-N-acetyltransferase | 25.11 ± 6.17 |
| Sulfonamide-resistant dihydropteroate synthase Sul1 | 7.72 ± 3.73 |
| Tetracycline efflux MFS transporter Tet(B) | 5.92 ± 1.67 |
| Class A beta-lactamase TEM-219 | 5.89 ± 1.74 |
| Class C extended-spectrum beta-lactamase EC-18 | 4.97 ± 1.73 |
| Meropenem | |
| Carbapenem-hydrolyzing class A beta-lactamase KPC-33 | 30.09 ± 5.21 |
| Bleomycin binding protein Ble-MBL | 9.55 ± 2.02 |
| OXA-23 family carbapenem-hydrolyzing class D beta-lactamase OXA-483 | 8.58 ± 3.25 |
| Class C extended-spectrum beta-lactamase EC-18 | 5.79 ± 2.05 |
| Class A beta-lactamase SHV-200 | 5.59 ± 2.74 |
| Tobramycin | |
| AAC(6′)-Ib family aminoglycoside 6′-N-acetyltransferase | 60.50 ± 5.02 |
| Aminoglycoside nucleotidyltransferase ANT(2”)-Ia | 17.91 ± 1.98 |
| Aminoglycoside N-acetyltransferase AAC(3)-IIc | 6.54 ± 1.24 |
| Aminoglycoside 6′-N-acetyltransferase AAC(6′)-Iq | 4.62 ± 1.51 |
| ArmA family 16S rRNA [guanine(1405)-N(7)]-methyltransferase | 1.89 ± 0.97 |
*Gain is the relative importance of the ARGC in a prediction model, reported here as mean with standard deviation computed over 51 independent models for the same AB.